Update On Phase 3 Librexia ACS Trial

Refinitiv1분 미만 읽기

Bristol-Myers Squibb Co BMY:

UPDATE ON PHASE 3 LIBREXIA ACS TRIAL
BRISTOL-MYERS SQUIBB CO - LIBREXIA ACS TRIAL DISCONTINUED DUE TO EFFICACY CONCERNS
BRISTOL-MYERS SQUIBB CO - NO NEW SAFETY CONCERNS IDENTIFIED FOR MILVEXIAN
BRISTOL-MYERS SQUIBB CO - LIBREXIA AF AND STROKE STUDIES CONTINUE, DATA EXPECTED 2026

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

이 뉴스를 읽으려면 로그인하거나 평생 무료 계정을 만드십시오